Stock MIRM MIRUM PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Mirum Pharmaceuticals, Inc.

Equities

MIRM

US6047491013

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-17 pm EDT 		5-day change 1st Jan Change
24.07 USD -2.75% Intraday chart for Mirum Pharmaceuticals, Inc. -2.79% -18.46%
May. 10 Morgan Stanley Adjusts Price Target on Mirum Pharmaceuticals to $53 From $57, Keeps Overweight Rating MT
May. 08 Transcript : Mirum Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 08, 2024

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Mirum Pharmaceuticals’ LIVMARLI Data Showcased at ESPGHAN Annual Meeting
BU
Mirum Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(4)
AQ
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Morgan Stanley Adjusts Price Target on Mirum Pharmaceuticals to $53 From $57, Keeps Overweight Rating
MT
Transcript : Mirum Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 08, 2024
Mirum Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Earnings Flash (MIRM) MIRUM PHARMACEUTICALS Posts Q1 Revenue $69.2M, vs. Street Est of $70.2M
MT
Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
BU
Mirum Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference
BU
Mirum Announces Publication of Phase 3 MARCH Data in The Lancet Demonstrating Benefits of LIVMARLI (maralixibat) in patients with PFIC
BU
Mirum Pharmaceuticals, Inc Publication of Phase 3 MARCH Data in The Lancet Demonstrating Benefits of LIVMARLI (maralixibat) in patients with PFIC
CI
Mirum Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
BU
Stifel Initiates Mirum Pharmaceuticals With Buy Rating, $48 Price Target
MT
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Mirum Pharmaceuticals LIVMARLI Receives Positive Reimbursement Recommendation by Canada s CADTH for Patients with Cholestatic Pruritusin Alagille Syndrome
AQ
Mirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome
BU
Mirum Pharmaceuticals, Inc. receives Positive Reimbursement Recommendation for Livmarli (Maralixibat Oral Solution) by Canada?S Cadth for Patients with Cholestatic Pruritus in Alagille Syndrome
CI
JMP Securities Raises Price Target on Mirum Pharmaceuticals to $72 From $69, Maintains Market Outperform Rating
MT
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday
MT
Sector Update: Health Care
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MIRM Stock
  4. News Mirum Pharmaceuticals, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW